On April 19th, DalCor Pharmaceuticals, a startup dedicated to the development of precision medicine for cardiovascular disease, announced that it has completed a $150 million financing plan that will use these funds to continue to develop dalcetrapib products for targeted treatment of cardiovascular diseases with specific genes. Disease patients. DalCor completed a $50 million Series A round of financing in 2015 and won a $100 million Series B investment this week led by Sanderling Ventures and André Desmarais. As a result, DalCor has accumulated an investment of $150 million.
Cardiovascular disease of concern to DalCor is the leading cause of death in the world. In the United States, the number of patients who die from cardiovascular disease each year amounts to 610,000. In China, the number of people dying from cardiovascular disease each year accounts for 21% of total deaths, second only to malignant tumors. To improve this situation, DalCor focused on the candidate drug dalcetrapib. Dalcetrapib is a cholesterol ester transporter (CETP) inhibitor. By modulating the activity of this protein, dalcetrapib can increase healthy high-density lipoprotein (HDL), thereby reducing the risk of cardiovascular disease. By analyzing existing clinical data, DalCor found that dalcetrapib can produce a therapeutic effect on a group of patients with acute coronary syndromes with specific genes. The ADCY9 gene in these patients has an AA polymorphism at the rs1967309 locus and accounts for nearly 20% of all subjects. When these patients took statins and used dalcetrapib, their cardiovascular disease rate was reduced by 39%. In addition, atherosclerotic plaques in their blood vessels also have a tendency to regress.
Dr. Robert McNeil, CEO of DalCor, said: "This clinical trial is a major advancement in cardiovascular medicine and will provide innovative treatments for patients with heart disease with specific genes. We believe that dalcetrapib has a significant reduction in specific genetic populations. The potential for cardiovascular disease risk, CETP inhibitors will bring long-term benefits. DalCor and its investors are working on the development of dalcetrapib, which will be the first personalized precision medicine for patients with cardiovascular disease with specific genetic maps. .
According to DalCor, they will use the funds for a phase III clinical trial of dalcetrapib. Beginning this month, DalCor plans to recruit 5,000 volunteers with acute coronary syndrome at the Montreal Heart Institute (MHI) to test the effects of dalcetrapib. We wish this Phase III clinical trial the best results and bring this precision treatment to patients as soon as possible.
Medical protective clothing refers to the protective clothing used by medical personnel (doctors, nurses, public health personnel, cleaning personnel, etc.) and people entering specific medical and health areas (such as patients, hospital visitors, personnel entering infected areas, etc.). Its function is to isolate germs, harmful ultrafine dust, acid and alkaline solutions, electromagnetic radiation, etc., to ensure the safety of personnel and keep the environment clean.
protective clothing,personal protection,disposable surgical protective clothing
Shanghai Rocatti Biotechnology Co.,Ltd , https://www.shljdmedical.com